Question 1

What is UCART19 and how does it work?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study of UCART19 in Pediatric Patients With Relapsed/Refractory B Acute Lymphoblastic Leukemia clinical trial (NCT02808442). Contact the study team or your healthcare provider for specific answers.

Question 2

What are the potential side effects of this treatment?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study of UCART19 in Pediatric Patients With Relapsed/Refractory B Acute Lymphoblastic Leukemia clinical trial (NCT02808442). Contact the study team or your healthcare provider for specific answers.

Question 3

How does this treatment compare to other options available for my child?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study of UCART19 in Pediatric Patients With Relapsed/Refractory B Acute Lymphoblastic Leukemia clinical trial (NCT02808442). Contact the study team or your healthcare provider for specific answers.

Question 4

What will the treatment process look like, including hospital visits?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study of UCART19 in Pediatric Patients With Relapsed/Refractory B Acute Lymphoblastic Leukemia clinical trial (NCT02808442). Contact the study team or your healthcare provider for specific answers.

Question 5

How will we monitor my child's response to the treatment?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study of UCART19 in Pediatric Patients With Relapsed/Refractory B Acute Lymphoblastic Leukemia clinical trial (NCT02808442). Contact the study team or your healthcare provider for specific answers.

Question 6

What are the eligibility criteria for this trial, and does my child meet them?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study of UCART19 in Pediatric Patients With Relapsed/Refractory B Acute Lymphoblastic Leukemia clinical trial (NCT02808442). Contact the study team or your healthcare provider for specific answers.

What this study is about